Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced complete first-in-human dose escalation data for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2). These data, from the global Phase 1/2 ReFocus study in patients with FGFR2-altered cholangiocarcinoma (CCA) and multiple other solid tumors, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2023. The data being presented at ASCO are generally consistent with those previously reported at the European Society for Medical Oncology (ESMO) Congress in September 2022.
Related Posts
Pot-Smoking Driver In Georgia Busted With $66K In Stolen Checks From New York
What started as a traffic stop for weed led authorities in Georgia to uncover a check-cashing and mail fraud scheme.
Price Over Earnings Overview: Vale
In the current market session, Vale Inc. (NYSE:VALE) share price is at $15.10, after a 1.31% drop. Over…
Elon Musk’s Tesla Is Reportedly Gearing Up For FSD Beta Launch In China Despite Regulatory Hurdles
Tesla Inc. (NASDAQ:TSLA) has begun preparations for launching FSD Beta in China, despite potential regulatory challenges, Electrek reports. …